BioLight Life Sciences Ltd (BOLT) - Total Assets
Based on the latest financial reports, BioLight Life Sciences Ltd (BOLT) holds total assets worth ILA42.41 Million ILA (≈ $113.71K USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See BOLT total equity for net asset value and shareholders' equity analysis.
BioLight Life Sciences Ltd - Total Assets Trend (2005–2025)
This chart illustrates how BioLight Life Sciences Ltd's total assets have evolved over time, based on quarterly financial data.
BioLight Life Sciences Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
BioLight Life Sciences Ltd's total assets of ILA42.41 Million consist of 57.5% current assets and 42.5% non-current assets.
| Asset Category | Amount (ILA) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ILA0.00 | 9.4% |
| Accounts Receivable | ILA307.00K | 0.7% |
| Inventory | ILA0.00 | 0.0% |
| Property, Plant & Equipment | ILA0.00 | 0.0% |
| Intangible Assets | ILA0.00 | 0.0% |
| Goodwill | ILA686.00K | 1.6% |
Asset Composition Trend (2005–2025)
This chart illustrates how BioLight Life Sciences Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of BioLight Life Sciences Ltd.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BioLight Life Sciences Ltd's current assets represent 57.5% of total assets in 2025, an increase from 0.0% in 2005.
- Cash Position: Cash and equivalents constituted 9.4% of total assets in 2025, down from 11.3% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, unchanged from 1.0% in 2005.
- Asset Diversification: The largest asset category is goodwill at 1.6% of total assets.
BioLight Life Sciences Ltd Competitors by Total Assets
Key competitors of BioLight Life Sciences Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Sagimet Biosciences Inc. Series A Common Stock
NASDAQ:SGMT
|
USA | $107.75 Million |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $1.53 Billion |
|
Inner Mongolia Furui Med Sci
SHE:300049
|
China | CN¥3.42 Billion |
|
Bio-Thera Solutions Ltd
SHG:688177
|
China | CN¥2.39 Billion |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
|
Gubra A/S
CO:GUBRA
|
Denmark | Dkr1.32 Billion |
BioLight Life Sciences Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 12.19 | 6.94 | 20.09 |
| Quick Ratio | 12.19 | 6.94 | 20.09 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ILA22.40 Million | ILA12.28 Million | ILA48.90 Million |
BioLight Life Sciences Ltd - Advanced Valuation Insights
This section examines the relationship between BioLight Life Sciences Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.66 |
| Latest Market Cap to Assets Ratio | 0.18 |
| Asset Growth Rate (YoY) | 24.3% |
| Total Assets | ILA42.41 Million |
| Market Capitalization | $7.66 Million USD |
Valuation Analysis
Below Book Valuation: The market values BioLight Life Sciences Ltd's assets below their book value (0.18x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: BioLight Life Sciences Ltd's assets grew by 24.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for BioLight Life Sciences Ltd (2005–2025)
The table below shows the annual total assets of BioLight Life Sciences Ltd from 2005 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ILA42.41 Million ≈ $113.71K |
+24.30% |
| 2024-12-31 | ILA34.12 Million ≈ $91.48K |
+2.00% |
| 2023-12-31 | ILA33.45 Million ≈ $89.68K |
-41.32% |
| 2022-12-31 | ILA57.01 Million ≈ $152.84K |
-11.16% |
| 2021-12-31 | ILA64.17 Million ≈ $172.04K |
-1.01% |
| 2020-12-31 | ILA64.83 Million ≈ $173.80K |
-13.50% |
| 2019-12-31 | ILA74.95 Million ≈ $200.94K |
-16.98% |
| 2018-12-31 | ILA90.28 Million ≈ $242.04K |
+264.58% |
| 2017-12-31 | ILA24.76 Million ≈ $66.39K |
-29.88% |
| 2016-12-31 | ILA35.31 Million ≈ $94.67K |
-44.19% |
| 2015-12-31 | ILA63.27 Million ≈ $169.63K |
+56.48% |
| 2014-12-31 | ILA40.43 Million ≈ $108.40K |
+17.77% |
| 2013-12-31 | ILA34.33 Million ≈ $92.04K |
-18.04% |
| 2012-12-31 | ILA41.89 Million ≈ $112.31K |
+41.37% |
| 2011-12-31 | ILA29.63 Million ≈ $79.44K |
+192.26% |
| 2010-12-31 | ILA10.14 Million ≈ $27.18K |
-54.92% |
| 2009-12-31 | ILA22.49 Million ≈ $60.29K |
-53.31% |
| 2006-12-31 | ILA48.16 Million ≈ $129.12K |
+136.21% |
| 2005-12-31 | ILA20.39 Million ≈ $54.66K |
-- |
About BioLight Life Sciences Ltd
BioLight Life Sciences Ltd. engages in the investment, development, management, and commercialization of products in the fields of advanced medical devices, pharmaceuticals, diagnostics, and digital medicine in Israel. The company offers TeaRx, a diagnostic platform intended for point-of-care testing of ophthalmic pathologies through multi-parameter composition analysis of the tear fluid; TeaRx D… Read more